Dr. Donald L. McNeil, MD

Dr. McNeil practices at Horizon Infusions in Blue Ash, Ohio.

Dr. McNeil's NPI, 1134199300, was assigned on January 23, 2006. Dr. McNeil holds Ohio license 35-05-4381.

Dr. McNeil's primary practice is Horizon Infusions, at 4260 Glendale Milford Rd, Blue Ash, OH 45242 in Hamilton County. The practice phone is (513) 769-2770.

Dr. McNeil's primary practice is Horizon Infusions in Blue Ash, Ohio. Dr. McNeil is also affiliated with Genesis Hospital. The medical group on file is Horizon Infusions. Dmand AI also links Dr. McNeil to 1 more hospital, 1 physician office, 1 group practice or clinic and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. McNeil practices, 4 sites in all. Vendor and product names are available with a free account.

Allergy and immunology is Dr. McNeil's primary specialty in the NPI Registry, under taxonomy code 207K00000X. Dr. McNeil is licensed in Ohio.

CMS data shows 679 Medicare services from Dr. McNeil across 5 procedure codes in 2024, for 126 Medicare patients. Medicare paid $8,252 for them. Every service was in an office.

CMS counts 126 Medicare patients who saw Dr. McNeil in 2024. The largest group is 65 to 74, with 73 patients. 75% of them have high cholesterol, and 71% have high blood pressure. Their average risk score is 1.46, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. McNeil's median patient age at 60, with 68% women.

In 2024, Dr. McNeil wrote 611 Medicare Part D claims for 124 patients. 62% of them were for generic drugs. CMS names the drug for 494 of them, across 20 drugs with 11 or more claims each, at $1,946,186 in total drug cost. In 2023, CMS named 783 claims across 31 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 84 out of 100 for Dr. McNeil for performance year 2024, reported as part of a group. Dr. McNeil accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. McNeil as offering telehealth.

Dmand AI links 6 papers to Dr. McNeil, published from 2020 to 2024. 2023 was the busiest year, with 2. The most frequent topics are Angioedemas, Hereditary, Double-Blind Method and Injections, Subcutaneous. Dr. McNeil's most frequent co-authors are Richard Lawrence Wasserman, MD, PhD, Oral Alpan, MD and Aleena Banerji, MD.

Dmand AI links Dr. McNeil to 9 clinical trials, 4 of them phase 3 studies. Conditions studied include Immunologic Deficiency Syndromes, Primary Immunodeficiency Diseases and Urticaria. Grifols Therapeutics LLC sponsors the most, 2. Open Payments lists research payments to Dr. McNeil that name 2 trials.

CMS Open Payments shows 612 general payments to Dr. McNeil from 37 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 29% of the total. BioCryst Pharmaceuticals, Inc. paid the most, $66,235. It also lists 22 research payments totaling $41,786 from 2016 to 2024, naming 2 clinical trials.